The subtle differences in heart failure outcomes across trials like EXAMINE and SAVOR-TIMI 53 suggest that certain DPP-4 inhibitors may impact heart failure risk differently, underscoring the need for a more individualized approach when choosing glucose-lowering therapies for patients with diabetes and cardiovascular disease. Here, DPP4 is linked to cardiovascular disorder.